The Oxford/AstraZeneca vaccine, which is now called Vaxzevria after a name change, is one of four vaccines licensed in the European Union to protect against Covid-19. So far, studies have shown it to be effective in preventing the disease and reducing the risk of hospitalization and death, although there have been cases of two types of low platelet thrombosis in immunized people.
As a result, the European Medicines Agency (EMA) has stressed the importance of rapid specialized medical treatment in the event of the appearance of various symptoms in the two weeks following vaccination, according to SINC, the scientific news agency of the Spanish Foundation for Science and Technology.
